Eurepa V 1 contains Voglibose. Eurepa V 1 uses:
Eurepa V 1 is used in diabetes mellitus (DM) for reduction in Post-Prandial Hyperglycaemia (PPHG), only when diet and/or exercise with lifestyle modification or Oral Hypoglycaemic Agents (OHAs) or insulin preparations, in addition to diet and/or exercise, do not result in an adequate glycaemic control.Thus, Eurepa V 1 is indicated:
Voligbose has general properties similar to acarbose and selectively inhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate, thereby suppressing sharp increase in post-prandial plasma glucose.
|Brand Name:||Eurepa V 1|
|Therapeutic Class:||Alpha-Glucosidase inhibitor|
|Manufacturer:||TORRENT PHARMACEUTICALS LTD|
|Last Updated:||2020-11-20 18:15:00|
Eurepa V 1 contains Voglibose 0.3 Mg. Eurepa V 1 doses
Normal Adult Dose: Usually, Eurepa V 1 tablets are orally administered in a single dose of 0.2 mg, 3 times a day, before each meal. If the effect is not sufficient, the quantity of a single dose may be increased up to 0.3 mg.
Pediatrics: The safety and effectiveness of Eurepa V 1 in children has not been established.
Geriatrics: Since elderly patients generally have a physiological hypofunction, it is desirable that such caution be taken as starting the administration at a lower dose (eg, 0.1 mg at a time). Furthermore, this drug should be carefully administered under close observation, through the course of the disease condition, with careful attention to the blood sugar level and the onset of gastrointestinal symptoms.
Diarrhoea, loose stools, abdominal pain, constipation, loss of appetite, urge to vomit (nausea), vomiting, heartburn, increased gas, and intestinal obstruction like symptoms due to increased intestinal gas. OHAs plus voglibose may cause hypoglycaemia (0.1% to <5%), delay in digestion and absorption of disaccharides, fulminant hepatitis, serious liver dysfunction with increased liver enzymes, jaundice, anaemia, numbness, edema, blurred vision, hot flushes, malaise, weakness, hyperkalemia, increased pancreatic enzyme (serum amylase).
Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level.
Careful Administration (should be administered with care in following patients):
Eurepa V 1 should be administered with care when co-administered with the following drugs:
Antidiabetic drugs: Derivative(s) of sulfonylamide and sulfonylurea, biguanide derivatives, insulin preparations and improving agents for insulin resistance.
For the concomitant use of antldlabetlc drugs and the drugs which enhance or diminish the hypoglycaemic action of antldlabetlc drugs:
Pregnancy: The safety of Eurepa V 1 in pregnancy has not been established. However, no adequate and well controlled studies have been done on pregnant women.
Lactation and Nursing Mothers: Although the levels of Eurepa V 1 reached in human milk are exceedingly low, it is recommended that Eurepa V 1 may not be administered to such women.
Contraindicated in patients with Hypersensitivity to Eurepa V 1 or to any of the excipients; Diabetic ketoacidosis, diabetic pre-coma; Severe infection, before and after operation or with serious trauma; Gastrointestinal obstruction or predisposed to it.
Dosage in Renal Failure: Eurepa V 1 is poorly absorbed after oral doses and renal excretion is negligible, suggesting that no dose adjustment is required. However, pharmacokinetic studies in patients with renal insufficiency are not available.
Unlike sulfonylureas or insulin, an overdose of Eurepa V 1 tablets will not result in hypoglycaemia. An overdose may result is transient increase in flatulence, diarrhoea and abdominal discomfort. Because of lack of extra-intestinal effects soon with Eurepa V 1, no serious systemic reactions are expected in the event of an overdose.
Keep in a cool and dry place. Keep out of the reach of children. Protect from light.
Eurepa V 1 Tablet price in India 140.25